enGene Holdings Inc. (ENGN) Stock Analysis & Investment Frameworks
enGene Holdings Inc. (ENGN) stock analysis on Invetso. Review enGene Holdings Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
enGene Holdings Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: CA
enGene Holdings Inc. Key Financial Metrics
- Market Cap: $104.55M
- Revenue: $N/A
- ROE: -2.10%
- ROIC: -1.61%
- Dividend Yield: N/A
About enGene Holdings Inc.
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
enGene Holdings Inc. Investment Frameworks
Invetso analyzes enGene Holdings Inc. (ENGN) across the following frameworks:
- enGene Holdings Inc. 10Y Growth Potential
- enGene Holdings Inc. Scenario Analysis
- enGene Holdings Inc. Risks & Opportunities
- enGene Holdings Inc. Economic Moat
- enGene Holdings Inc. Business Model
- enGene Holdings Inc. Management
- enGene Holdings Inc. SWOT Analysis
- enGene Holdings Inc. Porter's 5 Forces
- enGene Holdings Inc. PESTLE Analysis
- enGene Holdings Inc. ESG Analysis